Still have not contacted Jan West to try to persuade her of the folly of leaving renal especially too long. Might be better to leave it until after September 28. The argument has been made that the current directors know the US medical system. They obviously do not know one very important aspect of it - that is , the significance of the FDA Breakthrough Designation for a medical device. Ipd has that for SOZO for renal. It means that the FDA realises how important SOZO could be for monitoring fluid in endstage renal patients, and will help to fast track the process of approval (provided that Ipd can do the randomized trial to prove it, following the completed observational trial.) What sort of management is prepared to leave that important designation in abeyance for years - and what sort of board is prepared to believe that that is acceptable. Especially since it would be the least expensive "extra" thing to do on top of oncology , since 80% of the patients are with two organisations . I don't know whether they were asleep in the past, but they seem to be asleep to this now.
IPD Price at posting:
18.0¢ Sentiment: Hold Disclosure: Held
